TrialInternational journal of clinical oncology2008

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.

Yoh Watanabe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.